Christoph Wetz1, I Apostolova1, I G Steffen2, F Hofheinz3, C Furth2, D Kupitz1, J Ruf4, M Venerito5, S Klose6, Holger Amthauer7. 1. Department of Radiology and Nuclear Medicine, University Hospital, Otto-von-Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. 2. Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. 3. Institute of Radiopharmaceutical Cancer Research, PET Center, Helmholtz-Zentrum Dresden-Rossendorf, P.O. Box 510119, 01314, Dresden, Germany. 4. Department of Nuclear Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany. 5. Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital, Otto-von-Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. 6. Department of Nephrology and Hypertension, Diabetology and Endocrinology, University Hospital, Otto-von-Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. 7. Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. holger.amthauer@charite.de.
Abstract
PURPOSE: The purpose of this study was to assess the value of the spatial heterogeneity of somatostatin receptor (SSR) volume, quantified as asphericity (ASP), and to predict response to peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). PROCEDURES: From June 2011 to May 2013, patients suffering from GEP-NEN who underwent pretherapeutic [111In-DTPA0]octreotide scintigraphy (Octreoscan®) prior to [177Lu-DOTA0-Tyr3]octreotate ([177Lu]DOTATATE)-PRRT were enrolled in this retrospective evaluation. SSR expression in 20 NEN patients was qualitatively and quantitatively assessed using the Krenning score, the metastasis to liver uptake ratio (M/L ratio), and ASP at baseline. Response to PRRT was evaluated based on lesions, which were classified as responding lesions (RL) and non-responding lesions (NRL) after 4- and 12-month follow-ups. The values of the Krenning score, M/L ratio, and ASP for response prediction were compared by using the Mann-Whitney U test, Kruskal-Wallis test, and receiver operating characteristic (ROC) curves. RESULTS: Seventy-seven metastases (liver, n = 40; lymph node, n = 24; bone, n = 11; pancreas, n = 2) showed SSR expression. A higher ASP level was significantly associated with poorer response at both time points. ROC analyses revealed the highest area under the curve (AUC) for discrimination between RL and NRL for ASP after 4 months (AUC 0.97; p = 0.019) and after 12 months (AUC 0.96; p < 0.001), followed by the Krenning score (AUC 0.74; p = 0.082 and AUC 0.85; p < 0.001, respectively) and M/L ratio (AUC 0.77; p = 0.107 and AUC 0.82; p < 0.001). The optimal cutoff value for ASP was 5.12 % (sensitivity, 90 %; specificity, 93 %). CONCLUSION: Asphericity of SSR-expressing lesions in pretherapeutic single-photon emission computed tomography with integrated computed tomography (SPECT/CT) is a promising parameter for predicting response to PRRT in gastroenteropancreatic neuroendocrine neoplasms.
PURPOSE: The purpose of this study was to assess the value of the spatial heterogeneity of somatostatin receptor (SSR) volume, quantified as asphericity (ASP), and to predict response to peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). PROCEDURES: From June 2011 to May 2013, patients suffering from GEP-NEN who underwent pretherapeutic [111In-DTPA0]octreotide scintigraphy (Octreoscan®) prior to [177Lu-DOTA0-Tyr3]octreotate ([177Lu]DOTATATE)-PRRT were enrolled in this retrospective evaluation. SSR expression in 20 NEN patients was qualitatively and quantitatively assessed using the Krenning score, the metastasis to liver uptake ratio (M/L ratio), and ASP at baseline. Response to PRRT was evaluated based on lesions, which were classified as responding lesions (RL) and non-responding lesions (NRL) after 4- and 12-month follow-ups. The values of the Krenning score, M/L ratio, and ASP for response prediction were compared by using the Mann-Whitney U test, Kruskal-Wallis test, and receiver operating characteristic (ROC) curves. RESULTS: Seventy-seven metastases (liver, n = 40; lymph node, n = 24; bone, n = 11; pancreas, n = 2) showed SSR expression. A higher ASP level was significantly associated with poorer response at both time points. ROC analyses revealed the highest area under the curve (AUC) for discrimination between RL and NRL for ASP after 4 months (AUC 0.97; p = 0.019) and after 12 months (AUC 0.96; p < 0.001), followed by the Krenning score (AUC 0.74; p = 0.082 and AUC 0.85; p < 0.001, respectively) and M/L ratio (AUC 0.77; p = 0.107 and AUC 0.82; p < 0.001). The optimal cutoff value for ASP was 5.12 % (sensitivity, 90 %; specificity, 93 %). CONCLUSION: Asphericity of SSR-expressing lesions in pretherapeutic single-photon emission computed tomography with integrated computed tomography (SPECT/CT) is a promising parameter for predicting response to PRRT in gastroenteropancreatic neuroendocrine neoplasms.
Authors: Constantin Lapa; Rudolf A Werner; Jan-Stefan Schmid; Laszló Papp; Norbert Zsótér; Johannes Biko; Christoph Reiners; Ken Herrmann; Andreas K Buck; Ralph A Bundschuh Journal: Nucl Med Biol Date: 2014-12-20 Impact factor: 2.408
Authors: F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff Journal: Nuklearmedizin Date: 2011-10-26 Impact factor: 1.379
Authors: Frank Hofheinz; Alexandr Lougovski; Klaus Zöphel; Maria Hentschel; Ingo G Steffen; Ivayla Apostolova; Florian Wedel; Ralph Buchert; Michael Baumann; Winfried Brenner; Jörg Kotzerke; Jörg van den Hoff Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-22 Impact factor: 9.236
Authors: Maciej Pech; Konrad Mohnike; Gero Wieners; Ewa Bialek; Oliver Dudeck; Max Seidensticker; Nils Peters; Peter Wust; Günther Gademann; Jens Ricke Journal: Strahlenther Onkol Date: 2008-05 Impact factor: 3.621
Authors: Ivayla Apostolova; Julian Rogasch; Ralph Buchert; Heinz Wertzel; H Jost Achenbach; Jens Schreiber; Sandra Riedel; Christian Furth; Alexandr Lougovski; Georg Schramm; Frank Hofheinz; Holger Amthauer; Ingo G Steffen Journal: BMC Cancer Date: 2014-12-01 Impact factor: 4.430
Authors: Fergus Davnall; Connie S P Yip; Gunnar Ljungqvist; Mariyah Selmi; Francesca Ng; Bal Sanghera; Balaji Ganeshan; Kenneth A Miles; Gary J Cook; Vicky Goh Journal: Insights Imaging Date: 2012-10-24
Authors: Rudolf A Werner; Harun Ilhan; Sebastian Lehner; László Papp; Norbert Zsótér; Imke Schatka; Dirk O Muegge; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Peter Bartenstein; Frank Bengel; Markus Essler; Constantin Lapa; Ralph A Bundschuh Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: Rudolf A Werner; Alexander Weich; Malte Kircher; Lilja B Solnes; Mehrbod S Javadi; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa Journal: Theranostics Date: 2018-11-29 Impact factor: 11.556
Authors: Christoph Wetz; Philipp Genseke; Ivayla Apostolova; Christian Furth; Sammy Ghazzawi; Julian M M Rogasch; Imke Schatka; Michael C Kreissl; Frank Hofheinz; Oliver S Grosser; Holger Amthauer Journal: PLoS One Date: 2019-05-15 Impact factor: 3.240